46 related articles for article (PubMed ID: 16239129)
1. The effects of intravenous tobramycin on renal tubular function in children with cystic fibrosis.
Glass S; Plant ND; Spencer DA
J Cyst Fibros; 2005 Dec; 4(4):221-5. PubMed ID: 16239129
[TBL] [Abstract][Full Text] [Related]
2. Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy.
Mulheran M; Degg C; Burr S; Morgan DW; Stableforth DE
Antimicrob Agents Chemother; 2001 Sep; 45(9):2502-9. PubMed ID: 11502521
[TBL] [Abstract][Full Text] [Related]
3. Exploration of the relationship between cumulative exposure to tobramycin and ototoxicity in patients with cystic fibrosis.
Madaule J; Valenzuela F; Mittaine M; Gallois Y; Baladi B; Murris M; Calmels MN; Concordet D; Gandia P
J Cyst Fibros; 2023 Sep; 22(5):944-948. PubMed ID: 37088635
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis.
Dong M; Rodriguez AV; Blankenship CA; McPhail G; Vinks AA; Hunter LL
J Antimicrob Chemother; 2021 Oct; 76(11):2923-2931. PubMed ID: 34379758
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Target Attainment for Tobramycin in Children and Adults with Cystic Fibrosis.
Struiken STL; Lobée D; Tuinen ELV; Touw DJ; Vaart HV; Bourgonje AR; Rottier BL; Koppelman GH; Mian P
J Clin Med; 2024 Apr; 13(9):. PubMed ID: 38731170
[No Abstract] [Full Text] [Related]
6. Correction to: Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis.
J Antimicrob Chemother; 2024 May; 79(5):1201. PubMed ID: 38489535
[No Abstract] [Full Text] [Related]
7. Single-arm, open-labelled, safety and tolerability of intrabronchial and nebulised bacteriophage treatment in children with cystic fibrosis and
Singh J; Fitzgerald DA; Jaffe A; Hunt S; Barr JJ; Iredell J; Selvadurai H
BMJ Open Respir Res; 2023 May; 10(1):. PubMed ID: 37160359
[TBL] [Abstract][Full Text] [Related]
8. Tobramycin Serum Concentrations in Tracheostomy-Dependent Children Receiving Inhaled Tobramycin.
Hughes KM; Cristea AI; Tillman EM
Pediatr Allergy Immunol Pulmonol; 2020 Jun; 33(2):92-95. PubMed ID: 35921575
[No Abstract] [Full Text] [Related]
9. Mapping Adverse Outcome Pathways for Kidney Injury as a Basis for the Development of Mechanism-Based Animal-Sparing Approaches to Assessment of Nephrotoxicity.
Mally A; Jarzina S
Front Toxicol; 2022; 4():863643. PubMed ID: 35785263
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and safety of tobramycin nebulization with the I-neb and PARI-LC Plus in children with cystic fibrosis: A randomized, crossover study.
van Velzen AJ; Uges JWF; Heijerman HGM; Arets BGM; Nuijsink M; van der Wiel-Kooij EC; van Maarseveen EM; van Zanten GA; Pullens B; Touw DJ; Janssens HM
Br J Clin Pharmacol; 2019 Sep; 85(9):1984-1993. PubMed ID: 31112621
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Tobramycin Exposure Predictions in Three Bayesian Forecasting Programmes Compared with Current Clinical Practice in Children and Adults with Cystic Fibrosis.
Burgard M; Sandaradura I; van Hal SJ; Stacey S; Hennig S
Clin Pharmacokinet; 2018 Aug; 57(8):1017-1027. PubMed ID: 29134570
[TBL] [Abstract][Full Text] [Related]
12. Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients.
Stehling F; Büscher R; Grosse-Onnebrink J; Hoyer PF; Mellies U
Pulm Med; 2017; 2017():2602653. PubMed ID: 28133546
[No Abstract] [Full Text] [Related]
13. Serum cystatin C for acute kidney injury evaluation in children treated with aminoglycosides.
Lau L; Al-Ismaili Z; Harel-Sterling M; Pizzi M; Caldwell JS; Piccioni M; Lands LC; Mottes T; Devarajan P; Goldstein SL; Bennett MR; Zappitelli M
Pediatr Nephrol; 2017 Jan; 32(1):163-171. PubMed ID: 27743042
[TBL] [Abstract][Full Text] [Related]
14. Previous aminoglycoside use and acute kidney injury risk in non-critically ill children.
Saban JA; Pizzi M; Caldwell J; Palijan A; Zappitelli M
Pediatr Nephrol; 2017 Jan; 32(1):173-179. PubMed ID: 27718084
[TBL] [Abstract][Full Text] [Related]
15. Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis.
Downes KJ; Dong M; Fukuda T; Clancy JP; Haffner C; Bennett MR; Vinks AA; Goldstein SL
J Antimicrob Chemother; 2017 Jan; 72(1):254-260. PubMed ID: 27585963
[TBL] [Abstract][Full Text] [Related]
16. Role of biomarkers of nephrotoxic acute kidney injury in deliberate poisoning and envenomation in less developed countries.
Mohamed F; Endre ZH; Buckley NA
Br J Clin Pharmacol; 2015 Jul; 80(1):3-19. PubMed ID: 26099916
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for chronic kidney disease in adults with cystic fibrosis.
Quon BS; Mayer-Hamblett N; Aitken ML; Smyth AR; Goss CH
Am J Respir Crit Care Med; 2011 Nov; 184(10):1147-52. PubMed ID: 21799076
[TBL] [Abstract][Full Text] [Related]
18. Renal function in pediatric cystic fibrosis patients in the first decade of life.
Prestidge C; Chilvers MA; Davidson AG; Cho E; McMahon V; White CT
Pediatr Nephrol; 2011 Apr; 26(4):605-12. PubMed ID: 21190043
[TBL] [Abstract][Full Text] [Related]
19. Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis.
Prayle A; Watson A; Fortnum H; Smyth A
Thorax; 2010 Jul; 65(7):654-8. PubMed ID: 20627927
[TBL] [Abstract][Full Text] [Related]
20. Tobramycin once- vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients.
Riethmueller J; Ballmann M; Schroeter TW; Franke P; von Butler R; Claass A; Junge S; Doering G; Stern M;
Infection; 2009 Oct; 37(5):424-31. PubMed ID: 19756418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
